- Home
- SGD vs SNOA Comparison
SGD vs SNOA Comparison
Compare SGD & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- SNOA
- Stock Information
- Founded
- SGD 2021
- SNOA 1999
- Country
- SGD United States
- SNOA United States
- Employees
- SGD N/A
- SNOA N/A
- Industry
- SGD
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- SNOA Health Care
- Exchange
- SGD Nasdaq
- SNOA Nasdaq
- Market Cap
- SGD 4.1M
- SNOA 3.7M
- IPO Year
- SGD N/A
- SNOA 2007
- Fundamental
- Price
- SGD $1.96
- SNOA $2.65
- Analyst Decision
- SGD
- SNOA
- Analyst Count
- SGD 0
- SNOA 0
- Target Price
- SGD N/A
- SNOA N/A
- AVG Volume (30 Days)
- SGD 615.6K
- SNOA 44.7K
- Earning Date
- SGD 01-01-0001
- SNOA 02-06-2025
- Dividend Yield
- SGD N/A
- SNOA N/A
- EPS Growth
- SGD N/A
- SNOA N/A
- EPS
- SGD N/A
- SNOA N/A
- Revenue
- SGD $173,188.00
- SNOA $13,547,000.00
- Revenue This Year
- SGD N/A
- SNOA $23.89
- Revenue Next Year
- SGD N/A
- SNOA $25.45
- P/E Ratio
- SGD N/A
- SNOA N/A
- Revenue Growth
- SGD N/A
- SNOA 11.81
- 52 Week Low
- SGD $1.45
- SNOA $2.44
- 52 Week High
- SGD $53.80
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- SGD 38.33
- SNOA 47.13
- Support Level
- SGD $1.81
- SNOA $2.52
- Resistance Level
- SGD $2.74
- SNOA $2.80
- Average True Range (ATR)
- SGD 0.32
- SNOA 0.13
- MACD
- SGD -0.05
- SNOA 0.00
- Stochastic Oscillator
- SGD 12.30
- SNOA 39.39
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.